期刊文献+

血浆D-二聚体在乙肝后肝硬化患者中的表达及与预后的关系 被引量:3

Expression of plasma D-dimer in patients with post-hepatitis B cirrhosis and its relationship with prognosis
下载PDF
导出
摘要 目的探讨D-二聚体在乙肝后肝硬化患者外周血表达情况及其与预后的关系。方法选择105例乙肝后肝硬化患者进行研究,其中Child-Pugh A级23例,B级56例,C级26例,同时选取30例健康体检者作为对照组,比较Child-Pugh各分级患者血浆D二聚体水平与对照组的差异;根据有无腹水和随访期内生存情况,分别将105例乙肝后肝硬化患者分为有腹水组和无腹水组及死亡组和生存组,分析D-二聚体表达水平与病情及预后的关系。结果患者组中Child-Pugh A级、B级、C级患者血浆D-二聚体表达水平分别为(1.570±0.046)μg/L、(1.647±0.047)μg/L、(1.727±0.055)μg/L,明显高于对照组的(0.467±0.307)μg/L,差异均有统计学意义(P均<0.05);腹水组患者血浆D二聚体水平为(1.910±0.404)μg/L,无腹水组患者血浆D二聚体水平为(0.890±0.036)μg/L,腹水组显著高于无腹水组(P<0.05);死亡组患者血浆D-二聚体水平为(2.561±0.372)μg/L,生存组患者血浆D-二聚体水平为(1.697±0.548)μg/L,死亡组显著高于生存组(P<0.05)。结论血浆D-二聚体表达水平与乙肝后肝硬化患者疾病严重程度有关,并对预后有一定的指导价值。 Objective It is to investigate the expression of D-dimer in peripheral blood of patients with post-hepatitis B cirrhosis and its relationship with prognosis. Methods 105 patients with post-hepatitis B cirrhosis were selected, including 23 cases of Child-Pugh A, 56 cases of Child-Pugh B, and 26 cases of Child-Pugh C. At the same time, 30 healthy subjects were selected as the control group. The difference in plasma D-dimer level between the patients of every Child-Pugh classification and the control group were compared.105 cases of patients with post-hepatitis B cirrhosis were respectively divided into ascites group and non-ascites group, death group and survival group according to the presence or absence of ascites and survival during the follow-up period. The relationship between the level of dimer expression and the condition and prognosis was analyzed. Results The expression levels of plasma D-dimer in the patients with Child-Pugh Class A, B and C in the patient group were(1.570±0.046)μg/L,(1.647±0.047)μg/L,(1.727±0.055)μg/L, respectively, which were significantly higher than that of the control group(0.467±0.307)μg/L, the differences were statistically significant(P<0.05). The level of plasma D-dimer in the ascites group was(1.910±0.404)μg/L, in patients without ascites was(0.890±0.036)μg/L, the level was significantly higher in the ascites group than that in the non-ascites group(P<0.05). The plasma D-dimer level in the death group was(2.561±0.372) Ug/L, in the survival group was(1.697±0.548)μg/L, and the level in the death group was significantly higher than that in the survival group(P<0.05). Conclusion The expression level of plasma D-dimer is related to the severity of disease in patients with post-hepatitis B cirrhosis, and has a certain guiding value for prognosis.
作者 郭晓会 GUO Xiaohui(The Affiliated Hospital of Hebei University of Engineering, Handan 056000, Hebei, China)
出处 《现代中西医结合杂志》 CAS 2019年第30期3346-3348,3420,共4页 Modern Journal of Integrated Traditional Chinese and Western Medicine
基金 河北省邯郸市科学技术研究与发展计划项目(1523108076-19)
关键词 血浆D-二聚体 肝硬化 乙型肝炎 预后 plasma D-dimer liver cirrhosis hepatitis B prognosis
  • 相关文献

参考文献10

二级参考文献63

  • 1姚光弼,朱玫,马秀云,蔡皓东.拉米夫定治疗HBeAg阳性慢性乙型肝炎患者7年结果总结[J].肝脏,2007,12(2):81-86. 被引量:26
  • 2罗生强,张玲霞.2007年美国慢性乙型肝炎诊治推荐意见简介[J].中华肝脏病杂志,2007,15(6):477-480. 被引量:58
  • 3陈明,林仲秋,陈勍,冯淑英.联用CA_(125)和D-二聚体检测在卵巢癌鉴别诊断中的作用研究[J].实用妇产科杂志,2007,23(8):475-477. 被引量:17
  • 4Tripodi A, Anstee QM, Sogaard KK, Primignani M, Valla DC.Hypercoagulability in cirrhosis: causes and consequences. JThromb Haemost 2011; 9: 1713-1723 [PMID: 21729237].
  • 5Okuda K, Ohnishi K, Kimura K, Matsutani S, Sumida M, Goto N,Musha H, Takashi M, Suzuki N, Shinagawa T. Incidence of portalvein thrombosis in liver cirrhosis. An angiographic study in 708patients. Gastroenterology 1985; 89: 279-286 [PMID: 4007419].
  • 6Yamashita Y, Bekki Y, Imai D, Ikegami T, Yoshizumi T, IkedaT, Kawanaka H, Nishie A, Shirabe K, Maehara Y. Efficacy ofpostoperative anticoagulation therapy with enoxaparin for portalvein thrombosis after hepatic resection in patients with liver cancer.Thromb Res 2014; 134: 826-831 [PMID: 25156238 DOI: 10.1016/j.thromres.2014.07.038].
  • 7Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V,Condat B, Denninger MH, Sauvanet A, Valla D, Durand F.Splanchnic vein thrombosis in candidates for liver transplantation:usefulness of screening and anticoagulation. Gut 2005; 54: 691-697[PMID: 15831918].
  • 8Zocco MA, Di Stasio E, De Cristofaro R, Novi M, Ainora ME,Ponziani F, Riccardi L, Lancellotti S, Santoliquido A, Flore R,Pompili M, Rapaccini GL, Tondi P, Gasbarrini GB, LandolfiR, Gasbarrini A. Thrombotic risk factors in patients with livercirrhosis: correlation with MELD scoring system and portal veinthrombosis development. J Hepatol 2009; 51: 682-689 [PMID:19464747].
  • 9Amitrano L, Guardascione MA, Brancaccio V, Margaglione M,Manguso F, Iannaccone L, Grandone E, Balzano A. Risk factorsand clinical presentation of portal vein thrombosis in patients withliver cirrhosis. J Hepatol 2004; 40: 736-741 [PMID: 15094219].
  • 10Amitrano L, Brancaccio V, Guardascione MA, Margaglione M,Iannaccone L, D'Andrea G, Marmo R, Ames PR, Balzano A.Inherited coagulation disorders in cirrhotic patients with portal veinthrombosis. Hepatology 2000; 31: 345-348 [PMID: 10655256].

共引文献652

同被引文献26

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部